Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.50 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14489820 | 1.00 | EGLN3 (0.50) | EGLN3GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL941137 | 1.00 | EGLN3 (0.50) | EGLN3GRIA1GRIA2GRIA4GRIK5 | |
| Hydrochloric Acid SCHEMBL25425659 | 0.98 | EGLN3 (0.49) | EGLN3GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL27535957 | 0.82 | EGLN3 (0.55) | EGLN3MEN1KMT2AALDH1A1HDAC1 | |
| SCHEMBL2302721 | 0.82 | EGLN3 (0.56) | EGLN3GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL23009540 | 0.82 | EGLN3 (0.43) | EGLN3MEN1KMT2AALDH1A1HDAC1 | |
| SCHEMBL15208002 | 0.82 | EGLN3 (0.56) | EGLN3GRIA1GRIA2GRIA4GRIK5 | |
| SCHEMBL2300220 | 0.81 | EGLN3 (0.54) | EGLN3MEN1KMT2A | |
| SCHEMBL2300214 | 0.81 | EGLN3 (0.54) | EGLN3MEN1KMT2A | |
| SCHEMBL16343554 | 0.80 | MEN1 (0.42) | EGLN3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2024-06-20 | — | — | US | claimed |
| CN-117750978-A | Synthetic peptide shuttle bioconjugates for intracellular cargo delivery | 费尔丹生物公司 | 2024-03-22 | — | — | CN | claimed |
| EP-4313159-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | Feldan Bio Inc. (CA) | 2024-02-07 | — | — | EP | claimed |
| US-20230399661-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2023-12-14 | — | — | US | claimed |
| US-20230383291-A1 | PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION | FELDAN BIO INC. (CA) | 2023-11-30 | — | — | US | claimed |
| EP-4232590-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGTH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | Feldan Bio Inc. (CA) | 2023-08-30 | — | — | EP | claimed |
| CN-116615205-A | Peptide-based transduction of non-anionic polynucleotide analogs for modulation of gene expression | 费尔丹生物公司 | 2023-08-18 | — | — | CN | claimed |
| CN-116615227-A | Minimum length shuttle peptide suitable for transduction of Cas9-RNP and other nucleoprotein loads and variants thereof | 费尔丹生物公司 | 2023-08-18 | — | — | CN | claimed |
| WO-2022204806-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | FELDAN BIO INC. (CA) | 2022-10-06 | — | — | WO | claimed |
| US-20220204561-A1 | PEPTIDE-BASED NON-PROTEINACEOUS CARGO DELIVERY | FELDAN BIO INC. (CA) | 2022-06-30 | — | — | US | claimed |
| WO-2022082315-A1 | SHUTTLE AGENT PEPTIDES OF MINIMAL LENGH AND VARIANTS THEREOF ADAPTED FOR TRANSDUCTION OF CAS9-RNP AND OTHER NUCLEOPROTEIN CARGOS | FELDAN BIO INC. (CA) | 2022-04-28 | — | — | WO | claimed |
| EP-3970801-A1 | RAS INHIBITORY PEPTIDE | Ichimaru Pharcos Co., Ltd. (JP) | 2022-03-23 | — | — | EP | claimed |
| CN-114008210-A | Peptide-based non-protein cargo delivery | 费尔丹生物公司 | 2022-02-01 | — | — | CN | claimed |
| CN-113727991-A | Ras inhibitory peptide | 一丸自然美健有限公司 | 2021-11-30 | — | — | CN | claimed |
| WO-2020230780-A1 | Ras INHIBITORY PEPTIDE | 一丸ファルコス株式会社 | 2020-11-19 | — | — | WO | claimed |
| EP-3335720-A1 | C-DI-GMP BINDING PEPTIDES | Universität Basel (CH) | 2018-06-20 | — | — | EP | claimed |
| EP-3727462-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLERD LTD (GB) | 2025-11-05 | — | — | EP | disclosed |
| US-12459974-B2 | Bicyclic peptide ligands specific for Nectin-4 | BICYCLETX LIMITED (GB) | 2025-11-04 | — | — | US | disclosed |
| US-6153591-A | PROTECTING NERVOUS SYSTEM FOLLOWING FOCAL ISCHEMIA AND GLOBAL ISCHEMIA; ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PRION DISEASES, PARKINSON'S DISEASE, MULTIPLE SCLEROSIS, AMYOTROPHIC LATERAL SCLEROSIS, ALOPACIA, RHEUMATOID ARTHRITIS | CYTOVIA, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| WO-1999047154-A1 | DIPEPTIDE CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459974-B2 | Bicyclic peptide ligands specific for Nectin-4 | NECTIN4, VCAM1, SIGLEC7 | EGLN3 4139/4885GRIA1 1183/4885GRIA2 1296/4885 |
| US-20240197896-A1 | SYNTHETIC PEPTIDE SHUTTLE AGENT BIOCONJUGATES FOR INTRACELLULAR CARGO DELIVERY | SCAMP2, SLC7A1, NUMA1 | EGLN3 4401/4885GRIA1 2216/4885GRIA2 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.